0001823239FALSE00018232392024-12-182024-12-18


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 18, 2024

Maravai LifeSciences Holdings, Inc.
(Exact name of registrant as specified in its charter)

Delaware001-3972585-2786970
(State or other jurisdiction
of incorporation)		(Commission
File Number)		(IRS Employer
Identification No.)
10770 Wateridge Circle Suite 200
San Diego, California
92121
(Address of principal executive offices)(Zip Code)
(858) 546-0004
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading
Symbol(s)		Name of each exchange
on which registered
Class A Common Stock, $0.01 par valueMRVIThe Nasdaq Stock Market LLC
(Nasdaq Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revisited financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 8.01. Other Events.

On December 18, 2024, Maravai Intermediate Holdings, LLC (“Maravai Intermediate”), a subsidiary of Maravai LifeSciences Holdings, Inc., voluntarily pre-paid, using cash on hand, $228 million of aggregate principal amount of the outstanding term loan (the “Term Loan”) provided under the previously disclosed Credit Agreement, dated as of October 19, 2020, among Maravai Intermediate, Cygnus Technologies, LLC (“Cygnus”), TriLink Biotechnologies, LLC (“TriLink” and together with Maravai Intermediate and Cygnus, the “Borrowers”), Maravai TopCo Holdings, LLC, each lender from time to time party thereto, and Morgan Stanley Senior Funding, Inc., as administrative agent and collateral agent (as amended, the “Credit Agreement”). After giving effect to this prepayment of principal, the aggregate remaining principal balance outstanding under the Term Loan is approximately $300 million. There were no prepayment penalties associated with this prepayment of principal.

As of the date hereof, $167 million in aggregate borrowing capacity remained available to the Borrowers under the revolving credit facility provided under the Credit Agreement.






SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARAVAI LIFESCIENCES HOLDINGS, INC.
Date: December 18, 2024
By:/s/ Kevin M. Herde
Name:Kevin M. Herde
Title:Chief Financial Officer

v3.24.4
Cover
Dec. 18, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 18, 2024
Entity Registrant Name Maravai LifeSciences Holdings, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-39725
Entity Tax Identification Number 85-2786970
Entity Address, Address Line One 10770 Wateridge Circle
Entity Address, Address Line Two Suite 200
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code 858
Local Phone Number 546-0004
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Class A Common Stock, $0.01 par value
Trading Symbol MRVI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001823239
Amendment Flag false
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Maravai LifeSciences Charts.
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Maravai LifeSciences Charts.